mhurhangee/ep-ind-claims huggingface dataset:
A method of making a carbon electrode, suitable for use as an anode in an aluminum reduction cell, which comprises mixing an aggregate, comprising a mixture of particulate shot coke, and a particulate carbonaceous material other than shot coke with coal tar pitch or combination pitch at an elevated temperature to form a paste wherein said aggregate comprises a combination of coarse particles including recycled anode butts, medium, and fine particles and said particulate shot coke comprises a majority of said fine particles, and said paste comprises from about 80 to about 90%, by weight, of said aggregate and from about 10 to about 20%, by weight, of said coal tar pitch or combination pitch; forming said paste into a solid body; and baking said solid body at an elevated temperature to form said carbon electrode.
A process for preparing dioxolane comprising the steps of a) feeding a first feed stream containing ethylene glycol and a second feed stream containing formaldehyde and methanol in aqueous solution to a reaction distillation device and reacting ethylene glycol and formaldehyde in aqueous solution in the presence of at least one catalyst to obtain a raw product which comprises water, dioxolane and methanol, b) transferring a distillate stream containing raw product from the top of the reaction distillation device to a phase separation unit, wherein an organic extracting agent is present in the phase separation unit, c) transferring an organic fraction stream from the phase separation unit to an upper part of a purification column, withdrawing a bottom product stream containing dioxolane from the purification column, and recycling a distillate stream from the purification column to the phase separation unit, d) transferring an aqueous fraction stream from the phase separation unit to a waste water column, withdrawing a waste water stream from the bottom of the waste water column, withdrawing a side stream from a stage between the feed stage and the reflux stage of the waste water column and recycling this stream to the phase separation unit, and withdrawing a distillate stream containing methanol from the waste water column. a) feeding a first feed stream containing ethylene glycol and a second feed stream containing formaldehyde and methanol in aqueous solution to a reaction distillation device and reacting ethylene glycol and formaldehyde in aqueous solution in the presence of at least one catalyst to obtain a raw product which comprises water, dioxolane and methanol, b) transferring a distillate stream containing raw product from the top of the reaction distillation device to a phase separation unit, wherein an organic extracting agent is present in the phase separation unit, c) transferring an organic fraction stream from the phase separation unit to an upper part of a purification column, withdrawing a bottom product stream containing dioxolane from the purification column, and recycling a distillate stream from the purification column to the phase separation unit, d) transferring an aqueous fraction stream from the phase separation unit to a waste water column, withdrawing a waste water stream from the bottom of the waste water column, withdrawing a side stream from a stage between the feed stage and the reflux stage of the waste water column and recycling this stream to the phase separation unit, and withdrawing a distillate stream containing methanol from the waste water column.
A TLC plate comprising: a substrate; a separating medium layer stacked on the substrate; and a permeation layer stacked on the separating medium layer and allowing permeation of a target substance separated in the separating medium layer, wherein the separating medium layer has a separating property for the target substance and optical responsiveness for ultraviolet rays, and the permeation layer has an optical responsiveness for ultraviolet rays different from that of the separating medium layer, the TLC plate characterized in that the permeation layer is discontinuously stacked along the development direction of the TLC plate. a substrate; a separating medium layer stacked on the substrate; and a permeation layer stacked on the separating medium layer and allowing permeation of a target substance separated in the separating medium layer, wherein the separating medium layer has a separating property for the target substance and optical responsiveness for ultraviolet rays, and the permeation layer has an optical responsiveness for ultraviolet rays different from that of the separating medium layer, the TLC plate characterized in that the permeation layer is discontinuously stacked along the development direction of the TLC plate.
Corner transmission for the perpendicular transmission of the sliding movement of sliding slats and coupler locks of fittings of a window leaf, whereby the corner transmission comprises a corner piece with a first leg and a second leg, and whereby the coupler lock is slideable over the first leg, characterised in that the coupler lock is provided with a pre-mounted locking piece that snaps into place on the corner piece or on the leaf when the lock position of the window is reached the first time and whereby the locking piece uncouples from the coupler lock and remains near the corner of the corner piece when the coupler lock leaves the lock position again.
A friction stir welding tool made of a cemented carbide comprising WC grains in a binder phase, wherein said cemented carbide comprises from 3 wt-% to 10 wt-% Ni, characterised in that the outer surface of said welding tool is completely coated with a surface coating comprising Al 2 O 3 and said surface coating comprises an outermost surface coating of Al 2 O 3 and an intermediate surface coating of TiN.
A silicon oxide-coated zinc oxide formed by coating surfaces of zinc oxide particles with a silicon oxide coating, wherein an average particle diameter of the zinc oxide particles is in a range of more than 50 nm and 500 nm or less, when an abundance ratio of silicon in the silicon oxide coating in a Q 3 environment is indicated by Q 3, and an abundance ratio in a Q 4 environment is indicated by Q 4, Q 3 +Q 4 ≥0.6 and Q 4 /(Q 3 +Q 4)≥0.5, and wherein the degree of condensation of silicon oxide is determined by measuring the NMR spectrum of the silicon oxide-coated zinc oxide using solid-state 29 Si MAS-nuclear magnetic resonance spectroscopy.
A compound represented by Formula I: or a pharmaceutically acceptable salt, thereof, wherein: Ar is an aryl group; Ar 1 is an aryl group; Xis R is selected from the group consisting of lower alkyl, OC R 4, (CR 1 R 2) a C OR 3, (CR 1 R 2) a OR 3, (CR 1 R 2) a N(R 4)C R 3, (CR 1 R 2) a C N(R 3) 2, (CR 1 R 2) a N(R 4)C OR 3, (CR 1 R 2) a N(R 4)C N(R 3) 2,(CR 1 R 2) a N(R 3) 2, wherein N(R 3) 2 may form a heterocyclic ring optionally substituted with one or more of halogen and lower alkyl; R 1, R 2 and R 4 are independently selected from the group consisting of hydrogen, halogen and lower alkyl; R 3 is selected from the group consisting of hydrogen and lower alkyl; R 5 is selected from hydrogen and lower alkyl; R 6 is selected from hydrogen and lower alkyl; a is 0 or an integer of from 1 to 4; and n is 0 or an integer of from 1 to 4, the term lower alkyl refers to an alkyl group of from 1 to 7 carbons. Ar is an aryl group; Ar 1 is an aryl group; Xis R is selected from the group consisting of lower alkyl, OC R 4, (CR 1 R 2) a C OR 3, (CR 1 R 2) a OR 3, (CR 1 R 2) a N(R 4)C R 3, (CR 1 R 2) a C N(R 3) 2, (CR 1 R 2) a N(R 4)C OR 3, (CR 1 R 2) a N(R 4)C N(R 3) 2,(CR 1 R 2) a N(R 3) 2, wherein N(R 3) 2 may form a heterocyclic ring optionally substituted with one or more of halogen and lower alkyl; R 1, R 2 and R 4 are independently selected from the group consisting of hydrogen, halogen and lower alkyl; R 3 is selected from the group consisting of hydrogen and lower alkyl; R 5 is selected from hydrogen and lower alkyl; R 6 is selected from hydrogen and lower alkyl; a is 0 or an integer of from 1 to 4; and n is 0 or an integer of from 1 to 4, the term lower alkyl refers to an alkyl group of from 1 to 7 carbons.
A system for localizing a body structure in dosimetry of a target tissue or organ, said system comprising: an ultrasound probe for sweeping a field of view of said target tissue or organ; a medical tool comprising at least one embedded ultrasound sensor for insertion in said body structure; and a controller for determining locations of the at least one ultrasound sensor based on output signals of said at least one ultrasound sensor during said sweeping and for delineating a course of said body structure based on the determined locations of said at least one ultrasound sensor. an ultrasound probe for sweeping a field of view of said target tissue or organ; a medical tool comprising at least one embedded ultrasound sensor for insertion in said body structure; and a controller for determining locations of the at least one ultrasound sensor based on output signals of said at least one ultrasound sensor during said sweeping and for delineating a course of said body structure based on the determined locations of said at least one ultrasound sensor.
An inkjet printing liquid containing thermally reactive composite resin particles in an aqueous medium, wherein the thermally reactive composite resin particles contain: a) at least one thermal cross-linker having an average molecular weight of less than 2000; and b) at least one polymeric resin containing functional groups suitable for reacting with the thermal cross-linker. a) at least one thermal cross-linker having an average molecular weight of less than 2000; and b) at least one polymeric resin containing functional groups suitable for reacting with the thermal cross-linker.
An automated guided vehicle (10, 110) configured to operate with a navigation and guidance system, said AGV (10, 110) comprising: a base frame configured to support a material handling apparatus; a plurality of support wheel assemblies (18a-d) attached at peripheral portions of the base frame and configured to movably support the base frame away from a ground surface; a pair of drive wheel assemblies (20a, 20b) disposed between at least two of the plurality of support wheel assemblies (18a-d) and configured to propel the AGV (10, 110) over the ground surface; and a suspension system, which is configured to bias the pair of drive wheel assemblies (20a, 20b) against the ground surface to maintain friction of the drive wheel assemblies (20a, 20b) against the ground surface, characterized in that the suspension system having intersecting swing arms (24a, 24b) that pivotally mount at the base frame and independently attach at each of the drive wheel assemblies (20a, 20b), wherein the intersecting swing arms (24a, 24b) are intersecting when viewed from a front or rear end of the AGV (10, 110). a base frame configured to support a material handling apparatus; a plurality of support wheel assemblies (18a-d) attached at peripheral portions of the base frame and configured to movably support the base frame away from a ground surface; a pair of drive wheel assemblies (20a, 20b) disposed between at least two of the plurality of support wheel assemblies (18a-d) and configured to propel the AGV (10, 110) over the ground surface; and a suspension system, which is configured to bias the pair of drive wheel assemblies (20a, 20b) against the ground surface to maintain friction of the drive wheel assemblies (20a, 20b) against the ground surface, characterized in that the suspension system having intersecting swing arms (24a, 24b) that pivotally mount at the base frame and independently attach at each of the drive wheel assemblies (20a, 20b), wherein the intersecting swing arms (24a, 24b) are intersecting when viewed from a front or rear end of the AGV (10, 110).
A mutant isocitrate dehydrogenase 1 inhibitor for use in a method of treating acute myelogenous leukemia, comprising administering to a subject a therapeutically effective amount of an isocitrate dehydrogenase 1 inhibitor and a) an induction therapy regimen consisting of a combination of cytarabine and daunorubicin or a combination of cytarabine and idarubicin; and b) a consolidation therapy regimen consisting of cytarabine; wherein the mutant IDH1 inhibitor is -N-( -1-(2-chlorophenyl)-2-((3,3-difluorocyclobutyl)amino)-2-oxoethyl)-1-(4-cyanopyridin-2-yl)-N-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide (COMPOUND 2), having the following formula: or a pharmaceutically acceptable salt, solvate, tautomer, stereoisomer, isotopologue, or a polymorph thereof and is administered with both the induction and the consolidation therapy, and wherein the AML is characterized by the presence of a mutant allele of IDH1. a) an induction therapy regimen consisting of a combination of cytarabine and daunorubicin or a combination of cytarabine and idarubicin; and b) a consolidation therapy regimen consisting of cytarabine; wherein the mutant IDH1 inhibitor is -N-( -1-(2-chlorophenyl)-2-((3,3-difluorocyclobutyl)amino)-2-oxoethyl)-1-(4-cyanopyridin-2-yl)-N-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide (COMPOUND 2), having the following formula:
A method for controlling generation of biologically desirable voids in an implant having an outer surface and having a pre-formed substantially interconnected porous structure suitable for placement in proximity to bone tissue in a patient, comprising: selecting at least one osteoinductive water-soluble inorganic material having a desired particle size and dissolution rate; and mixing the water-soluble inorganic material within the pre-formed substantially interconnected porous structure formed of a poorly water-soluble matrix material disposed on at least a portion of the outer surface and defining interstices, wherein the matrix material forms the substantially interconnected porous structure before the water-soluble inorganic material is mixed within the matrix material and prior to placement in a patient, the mixing including blending the water-soluble inorganic material within at least some of the interstices and attaching or fixing the water-soluble inorganic material to the matrix material; so that after placement of the porous matrix structure formed of the matrix material mixed with the water-soluble inorganic material into the patient in proximity to bone tissue, bodily fluids are capable of dissolving the water-soluble inorganic material at a predetermined rate to generate biologically desirable voids in the matrix structure, having an average cross-sectional dimension greater than 100 microns, by gradually exposing more of the interstices into which bone tissue can then grow to facilitate fixation of the implant within the patient. selecting at least one osteoinductive water-soluble inorganic material having a desired particle size and dissolution rate; and mixing the water-soluble inorganic material within the pre-formed substantially interconnected porous structure formed of a poorly water-soluble matrix material disposed on at least a portion of the outer surface and defining interstices, wherein the matrix material forms the substantially interconnected porous structure before the water-soluble inorganic material is mixed within the matrix material and prior to placement in a patient, the mixing including blending the water-soluble inorganic material within at least some of the interstices and attaching or fixing the water-soluble inorganic material to the matrix material; so that after placement of the porous matrix structure formed of the matrix material mixed with the water-soluble inorganic material into the patient in proximity to bone tissue, bodily fluids are capable of dissolving the water-soluble inorganic material at a predetermined rate to generate biologically desirable voids in the matrix structure, having an average cross-sectional dimension greater than 100 microns, by gradually exposing more of the interstices into which bone tissue can then grow to facilitate fixation of the implant within the patient.
Berberine for use in a method for improving gut microbiota population in a subject having obesity or insulin resistance, wherein improving the gut microbiota population is characterized by selectively increasing a first gut microbiota population while simultaneously decreasing a second gut microbiota population to increase short-chain fatty acid level in the subject or reduce subject insulin resistance, the method comprising administering to the subject berberine at a dosage of 100mg/Kg body weight, wherein the first gut microbiota population comprises Allobaculum, Bacteroides, Blautia, Butyricicoccus, Dorea, Holdemania, Lawsonia, Parabacteroides, Phascolarctobacterium, Sedimentibacter, or a combination thereof, and wherein the second gut microbiota population comprises Alistipes, Anaeroplasma, Barnesiella, Bifidobacterium, Butyricimonas, Butyrivibrio, Coprococcus, Fastidiosipila, Helicobacter, Hespellia, Marvinbryantia, Oribacterium, Oscillibacter, Prevotella, Roseburia, Ruminococcus, or a combination thereof.
A retention system for an oral appliance, comprising: a dental implant configured to be inserted within a bone in an oral cavity of a patient; an abutment securable to the dental implant; one or more shape memory elements secured along an upper portion of the abutment, wherein the one or more shape memory elements have an exposed portion when the dental implant is configured to be inserted within the oral cavity of the patient, wherein the exposed portion of the one or more shape memory elements are each sized to extend longitudinally along the abutment with a straightened portion and a curved or arcuate portion which projects radially, an oral prosthesis defining a receiving channel for positioning upon the abutment; and, an energy source configured to apply heat or electrical energy to the one or more shape memory elements, wherein the one or more shape memory elements are actuatable upon application of heat or electrical energy to transition between a radially extended locking configuration and a low-profile configuration, wherein the one or more shape memory elements retract to the low-profile configuration upon application of heat or electrical energy in order to position the oral prosthesis upon the abutment, and wherein upon removal of the heat or electrical energy will allow the one or more shape memory elements to be able to reconfigure into the radially extended locking configuration so that the oral prosthesis will be lockingly positioned on the abutment. a dental implant configured to be inserted within a bone in an oral cavity of a patient; an abutment securable to the dental implant; one or more shape memory elements secured along an upper portion of the abutment, wherein the one or more shape memory elements have an exposed portion when the dental implant is configured to be inserted within the oral cavity of the patient, wherein the exposed portion of the one or more shape memory elements are each sized to extend longitudinally along the abutment with a straightened portion and a curved or arcuate portion which projects radially, an oral prosthesis defining a receiving channel for positioning upon the abutment; and, an energy source configured to apply heat or electrical energy to the one or more shape memory elements, wherein the one or more shape memory elements are actuatable upon application of heat or electrical energy to transition between a radially extended locking configuration and a low-profile configuration, wherein the one or more shape memory elements retract to the low-profile configuration upon application of heat or electrical energy in order to position the oral prosthesis upon the abutment, and wherein upon removal of the heat or electrical energy will allow the one or more shape memory elements to be able to reconfigure into the radially extended locking configuration so that the oral prosthesis will be lockingly positioned on the abutment.
A switching arrangement (15, 115, 215) for reducing contactor wear of an energy storage system (30, 130, 230) having a plurality of battery packs (31, 32, 33, 131, 132, 231, 232) arranged in parallel for powering a load (110, 210), the switching arrangement comprising: - a contactor (141, 142, 241, 242) for each battery pack, the contactors being configured to connect and disconnect the battery packs relative the load by closing and opening, respectively, characterised by: - an electric arc reducing circuitry associated to one of the contactors, wherein the switching arrangement is configured to electrically disconnect the battery packs from the load by means of the contactors such that the contactor being associated with the electric arc reducing circuitry is opened last. - a contactor (141, 142, 241, 242) for each battery pack, the contactors being configured to connect and disconnect the battery packs relative the load by closing and opening, respectively, characterised by: - an electric arc reducing circuitry associated to one of the contactors, - an electric arc reducing circuitry associated to one of the contactors,
A process for manufacturing wood board, comprising the steps: (a) providing wood pieces; (b) applying a carbohydrate binder composition to the wood pieces provided in step (a); (c) forming the wood pieces obtained in step (b) into a sheet; (d) heating and pressing the sheet obtained in step (c) to obtain a cured wood board; and (e) post-curing the wood board obtained in step (d). (a) providing wood pieces; (b) applying a carbohydrate binder composition to the wood pieces provided in step (a); (c) forming the wood pieces obtained in step (b) into a sheet; (d) heating and pressing the sheet obtained in step (c) to obtain a cured wood board; and (e) post-curing the wood board obtained in step (d).
An ALK1-Fc fusion protein comprising a polypeptide having an amino acid sequence that is at least 97% identical to the sequence of amino acids 22-118 of SEQ ID NO: 1, wherein the ALK1-Fc fusion protein inhibits angiogenesis stimulated by VEGF, FGF and GDF7, for use in: (a) inhibiting angiogenesis in a mammal; or (b) treating rheumatoid arthritis in a mammal.
An agent for dyeing and/or lightening keratin fibers, in particular human hair, characterized in that it contains, in a cosmetic carrier, (a) at least one compound of formula (Ia) where A - represents a physiologically acceptable anion, and (b) at least one phosphate surfactant. (a) at least one compound of formula (Ia) where A - represents a physiologically acceptable anion, and (b) at least one phosphate surfactant.
A method of eliminating wastewater in a reverse osmosis apparatus that supplies water to an institutional dishmachine, the method comprising: a) introducing a water stream into the reverse osmosis apparatus to split the water stream into a permeate rinse stream and a concentrate rinse stream; b) rinsing dishware during a rinse cycle of the institutional dishmachine with the concentrate rinse stream, wherein the concentrated rinse stream constitutes 60% or less of the total volume of water used in the rinse cycle; and c) rinsing the dishware during the rinse cycle of the institutional dishmachine with the permeate rinse stream after rinsing the dishware with the concentrate rinse stream; d) wherein a time ratio of use of the concentrate rinse stream to the permeate rinse stream is 3:2 or less; and e) wherein the permeate rinse stream has a total dissolved solids concentration of 200 parts per million or less. a) introducing a water stream into the reverse osmosis apparatus to split the water stream into a permeate rinse stream and a concentrate rinse stream; b) rinsing dishware during a rinse cycle of the institutional dishmachine with the concentrate rinse stream, wherein the concentrated rinse stream constitutes 60% or less of the total volume of water used in the rinse cycle; and c) rinsing the dishware during the rinse cycle of the institutional dishmachine with the permeate rinse stream after rinsing the dishware with the concentrate rinse stream; d) wherein a time ratio of use of the concentrate rinse stream to the permeate rinse stream is 3:2 or less; and e) wherein the permeate rinse stream has a total dissolved solids concentration of 200 parts per million or less.